Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Dec 11, 2019
Prof Ole De Backer (Rigshospitalet, Copenhagen, DK) provides an update from the GALILEO-4D trial, discussing the comparison of a Rivaroxaban-Based Strategy With an Antiplatelet-Based Strategy for the Prevention of Subclinical Leaflet Thrombosis in Transcatheter Aortic Valves.
Questions: 1.What is the GALILEO-4D study and how is it related to the main GALILEO trial? 2.What is the design of the study and what endpoints were aimed for? 3.What were the outcomes of the GALILEO-4D investigation? 4.How should this research influence future antithrombotic post-TAVR research?
Filmed on site by Radcliffe Cardiology at AHA 2019. Videographer: Tom Green & Dominic Woodruff
radcliffecardiology.com is a dynamic, digitally-focused producer & publisher of Cardiovascular, Renal and Metabolic (CVRM) content for physicians worldwide. Radcliffe Cardiology also has a dedicated eLearning platform, RC Academy, which uses innovative platforms to host digital webinars, live case broadcasts and video roundtable discussions.